tetano
Editor, Senior Moderator
Respir Investig
. 2020 Aug 28;S2212-5345(20)30117-9.
doi: 10.1016/j.resinv.2020.08.001. Online ahead of print.
Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases
Kota Murohashi[SUP] 1 [/SUP], Eri Hagiwara[SUP] 2 [/SUP], Takaaki Kitayama[SUP] 2 [/SUP], Takafumi Yamaya[SUP] 2 [/SUP], Katsuyuki Higa[SUP] 2 [/SUP], Yozo Sato[SUP] 2 [/SUP], Ryota Otoshi[SUP] 2 [/SUP], Ryota Shintani[SUP] 2 [/SUP], Hiroko Okabayashi[SUP] 2 [/SUP], Satoshi Ikeda[SUP] 2 [/SUP], Takashi Niwa[SUP] 2 [/SUP], Atsuhito Nakazawa[SUP] 2 [/SUP], Tsuneyuki Oda[SUP] 2 [/SUP], Ryo Okuda[SUP] 2 [/SUP], Akimasa Sekine[SUP] 2 [/SUP], Hideya Kitamura[SUP] 2 [/SUP], Tomohisa Baba[SUP] 2 [/SUP], Shigeru Komatsu[SUP] 2 [/SUP], Tae Iwasawa[SUP] 3 [/SUP], Takeshi Kaneko[SUP] 4 [/SUP], Takashi Ogura[SUP] 5 [/SUP]
Affiliations
Abstract
Although the use of corticosteroids is not recommended in the World Health Organization statement for the treatment of coronavirus disease 2019 (COVID-19), steroid therapy may be indicated for critical cases in specific situations. Here, we report the successful treatment of 11 cases of severe COVID-19 pneumonia with favipiravir and methylprednisolone. All cases were severe and patients required oxygen administration or had a blood oxygen saturation ≤93% on room air. All were treated with favipiravir and methylprednisolone, and 10 of 11 patients responded well and required no further oxygen supplementation or ventilator management. This study shows the importance of the early-stage use of a combination of favipiravir and methylprednisolone in severe cases to achieve a favorable clinical outcome.
Keywords: Favipiravir; Methylprednisolone; Novel coronavirus disease 2019; Severe illness.
. 2020 Aug 28;S2212-5345(20)30117-9.
doi: 10.1016/j.resinv.2020.08.001. Online ahead of print.
Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases
Kota Murohashi[SUP] 1 [/SUP], Eri Hagiwara[SUP] 2 [/SUP], Takaaki Kitayama[SUP] 2 [/SUP], Takafumi Yamaya[SUP] 2 [/SUP], Katsuyuki Higa[SUP] 2 [/SUP], Yozo Sato[SUP] 2 [/SUP], Ryota Otoshi[SUP] 2 [/SUP], Ryota Shintani[SUP] 2 [/SUP], Hiroko Okabayashi[SUP] 2 [/SUP], Satoshi Ikeda[SUP] 2 [/SUP], Takashi Niwa[SUP] 2 [/SUP], Atsuhito Nakazawa[SUP] 2 [/SUP], Tsuneyuki Oda[SUP] 2 [/SUP], Ryo Okuda[SUP] 2 [/SUP], Akimasa Sekine[SUP] 2 [/SUP], Hideya Kitamura[SUP] 2 [/SUP], Tomohisa Baba[SUP] 2 [/SUP], Shigeru Komatsu[SUP] 2 [/SUP], Tae Iwasawa[SUP] 3 [/SUP], Takeshi Kaneko[SUP] 4 [/SUP], Takashi Ogura[SUP] 5 [/SUP]
Affiliations
- PMID: 32893160
- DOI: 10.1016/j.resinv.2020.08.001
Abstract
Although the use of corticosteroids is not recommended in the World Health Organization statement for the treatment of coronavirus disease 2019 (COVID-19), steroid therapy may be indicated for critical cases in specific situations. Here, we report the successful treatment of 11 cases of severe COVID-19 pneumonia with favipiravir and methylprednisolone. All cases were severe and patients required oxygen administration or had a blood oxygen saturation ≤93% on room air. All were treated with favipiravir and methylprednisolone, and 10 of 11 patients responded well and required no further oxygen supplementation or ventilator management. This study shows the importance of the early-stage use of a combination of favipiravir and methylprednisolone in severe cases to achieve a favorable clinical outcome.
Keywords: Favipiravir; Methylprednisolone; Novel coronavirus disease 2019; Severe illness.